Focus Contact


LeafBio, Inc. is the commercialization arm of Mapp Biopharmaceutical.

News

August 12, 2014 at 8:30 AM - The available supply of ZMapp™ has been exhausted. We have complied with every request for ZMapp™ that had the necessary legal/regulatory authorization. It is the requestors’ decision whether they wish to make public their request, acquisition, or use of the experimental drug. Any decision to use ZMapp™ must be made by the patients’ medical team. Drug has been provided at no cost in all cases.

Monoclonal Antibody-based Filovirus Therapeutic Licensed to Leaf Biopharmaceutical July 15, 2014

Experimental Ebola Treatment Protects Some Primates Even After Disease Symptoms Appear August 21, 2013

ZMapp™ Information Sheet

ZMapp™ Frequently Asked Questions